A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women

NCT ID: NCT00860964

Last Updated: 2009-03-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 221 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1998-02-28
• Study Completion Date: 2006-12-31

Brief Summary

The purpose of this trial is to study the efficacy and safety of low dose of estradiol valerate in the prevention and treatment of postmenopausal osteoporosis.

Detailed Description

Research purposes: To assess the Impact of hormone therapy on quality of life in early post-menopausal women; To assess the Impact of hormone therapy on cardiovascular system in early post-menopausal women; To assess the Impact of hormone therapy on cognitive function in early post-menopausal women; To assess the Impact of hormone therapy on osteoporosis in early post-menopausal women.

Study Design:

The clinical trial research was divided into 2 groups. Treatment group given estradiol valerate 1mg/d, periodic application of medroxyprogesterone 6mg/d for 10 days, calcium 900mg/d, VitD200iu/d and exercise(Brisk walking every day 2 times, continued for 10 minutes each time). Control group given placebo, calcium,VitD and exercise were same with treatment group.

Conditions

Osteoporosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo, calcium 900mg/d, VitD200iu/d and exercise

estradiol valerate

Group Type: EXPERIMENTAL

estradiol valerate

Intervention Type: DRUG

estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise

Interventions

Placebo

Placebo, calcium 900mg/d, VitD200iu/d and exercise

Intervention Type: DRUG

estradiol valerate

estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

All patients meet the criteria:

1. Patients with informed consent.

2. Breast Cancer inform possible danger.

3. Physical and mental health.

Menopausal transition meet the criteria:

1. Age between 40 ~ 55 years old.

2. Women with Menopause syndrome or menstrual disorders.

3. The second to fourth lumbar spine bone mineral density to normal.

Early postmenopause meet the criteria:

1. Age between 45 ~ 60 years old.

2. Spontaneous amenorrhea for more than six months and less than 5 years.

3. The second to fourth lumbar spine bone mineral density was between -1 and -2.5 Standard deviation Compared with normal young women.

Exclusion Criteria

1. Tobacco or alcohol abuser.

2. History of various malignant diseases.

3. Women with Serious chronic diseases, such as liver and kidney dysfunction.

4. Women Suffering from endocrine diseases, such as Thyroid disease, Parathyroid disease,Adrenal disease and Osteomalacia.

5. Women with Long-term application of drugs, such as Antiepileptic drug, Adrenocorticotropic hormone, Diuretics and Heparin.

6. Women had used estrogen or calcitonin in the past 6 months.

7. Women has added higher than the physiological requirements VitD.

8. Who had taken bisphosphonates or sodium fluoride in the past 1 year.

9. Women had been taking Chinese medicines or other unregistered food in past 3 months.

10. Women with one of the following medical history or disease: Thrombophlebitis, estrogen-related thrombosis or thromboembolism, Cerebrovascular accident, with known or suspected estrogen-dependent tumor, undiagnosed vaginal bleeding, Cervical Pap smear graded at 3 or more, Serious uterine disorders, Serious breast disorders, Serious gallbladder disease, Severe hypertension and Hypercholesterolemia

11. Secondary osteoporosis.

12. Participants' lumbar spine anatomy(at least L1~L4) is not suitable to do dual-energy X-ray absorptiometry measured, such as obvious scoliosis, bone injury and Orthopedic surgery Sequelae.

13. Doctor consider inappropriate to participate in because of other diseases.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Peking Union Medical College

OTHER

Sponsor Role: lead

Principal Investigators

Shou Q Lin, PhD

Role: PRINCIPAL_INVESTIGATOR

Gynecological endocrinology & women's health centre of Peking Union Medical College Hospital

Other Identifiers

CMB 97-667

Identifier Type: -

Identifier Source: org_study_id